Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Abstract 6297: Mapping cellular interactions from spatially resolved transcriptomics data

Cancer Res (2025) 85 (8_Supplement_1): 6297.

https://doi.org/10.1158/1538-7445.AM2025-6297

Published: 21 April 2025

View articletitled, Abstract 6297: Mapping cellular interactions from spatially resolved transcriptomics data

Journal Articles

Abstract 5339: Single cell analysis enables tracking the evolution of resistance to CDK4/6 inhibitors in ER+ breast cancer

Yuki Matsunaga, Emma Aleksandrovic, Hima M. Patel, Dhivya R. Sudhan, Khushi Ahuja, Dan Ye, Chang-Ching A. Lin, Lei Guo, Cynthia X. Ma, Jeon Lee, Siyuan Zhang, Carlos L. Arteaga, Ariella B. Hanker

Cancer Res (2025) 85 (8_Supplement_1): 5339.

https://doi.org/10.1158/1538-7445.AM2025-5339

Published: 21 April 2025

View articletitled, Abstract 5339: Single cell analysis enables tracking the evolution of resistance to CDK4/6 inhibitors in ER+ breast cancer

Journal Articles

Abstract 3003: Targeting mechanisms of adaptive resistance to the PI3Kαmutant selective inhibitor RLY-2608 in HR+/PIK3CA mutant breast cancer

Fabiana Napolitano, Chang-Ching Lin, Khushi Ahuja, Dan Ye, María Rosario Chica-Parrado, Yasuaki Uemoto, Pamela Luna, Yuki Matsunaga, Saurabh Mendiratta, Nisha Unni, Jeon Lee, Ariella B. Hanker, Carlos L. Arteaga

Cancer Res (2025) 85 (8_Supplement_1): 3003.

https://doi.org/10.1158/1538-7445.AM2025-3003

Published: 21 April 2025

View articletitled, Abstract 3003: Targeting mechanisms of adaptive resistance to the PI3Kαmutant selective inhibitor RLY-2608 in HR+/PIK3CA mutant breast cancer

Journal Articles

Abstract 5332: Targeting CDK2 in estrogen receptor-positive/RB-deficient breast cancer

Chang-Ching A. Lin, Pamela Luna, Khushi Ahuja, Dan Ye, Yisheng V. Fang, Alec Trub, John Bisi, Jay Strum, Patrick Roberts, Jeon Lee, Ariella B. Hanker, Carlos L. Arteaga

Cancer Res (2025) 85 (8_Supplement_1): 5332.

https://doi.org/10.1158/1538-7445.AM2025-5332

Published: 21 April 2025

View articletitled, Abstract 5332: Targeting CDK2 in estrogen receptor-positive/RB-deficient breast cancer

Journal Articles

Abstract CT271: Neoadjuvant targeted therapy in stage I-III HER2-mutant lobular breast cancer

Laura C. Kennedy, Nisha Unni, Ariella B. Hanker, Carlos L. Arteaga

Cancer Res (2024) 84 (7_Supplement): CT271.

https://doi.org/10.1158/1538-7445.AM2024-CT271

Published: 05 April 2024

View articletitled, Abstract CT271: Neoadjuvant targeted therapy in stage I-III HER2-mutant lobular breast cancer

Journal Articles

Abstract 3308: A selective FGFR1/2 degrader overcomes endocrine resistance in ER+/FGFR1-amplified andFGFR1/2-mutant breast cancer

Yasuaki Uemoto, Chang-Ching Lin, Bingnan Wang, Dan Ye, Emmanuel Bikorimana, Alberto Servetto, Luigi Formisano, Fabiana Napolitano, Rosario Chica Parrado, Saurabh Mendiratta, Chuo Chen, Ariella B. Hanker, Carlos L. Arteaga

Cancer Res (2024) 84 (6_Supplement): 3308.

https://doi.org/10.1158/1538-7445.AM2024-3308

Published: 22 March 2024

View articletitled, Abstract 3308: A selective FGFR1/2 degrader overcomes endocrine resistance in ER+/FGFR1-amplified andFGFR1/2-mutant breast cancer

Journal Articles

Abstract 7592: Combined inhibition of CDK4/6 and AKT is highly active against the luminal androgen receptor (LAR) subtype of triple negative breast cancer (TNBC)

Rosario Chica-Parrado, Gun Min Kim, Yasuaki Uemoto, Dan Ye, Fabiana Napolitano, Chang-Ching Lin, Emmanuel Bikorimana, Kyung-min Lee, Saurabh Mendiratta, Ariella B. Hanker, Carlos L. Arteaga

Cancer Res (2024) 84 (6_Supplement): 7592.

https://doi.org/10.1158/1538-7445.AM2024-7592

Published: 22 March 2024

View articletitled, Abstract 7592: Combined inhibition of CDK4/6 and AKT is highly active against the luminal androgen receptor (LAR) subtype of triple negative breast cancer (TNBC)

Journal Articles

AXL/WRNIP1 Mediates Replication Stress Response and Promotes Therapy Resistance and Metachronous Metastasis in HER2⁺ Breast Cancer

Cancer Res (2024) 84 (5): 675–687.

https://doi.org/10.1158/0008-5472.CAN-23-1459

Published: 04 March 2024

View articletitled, AXL/WRNIP1 Mediates Replication Stress Response and Promotes Therapy Resistance and Metachronous Metastasis in HER2+ Breast Cancer

Includes: Supplementary data

Journal Articles

Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer

Arnaldo Marín, Abdullah Al Mamun, Hima Patel, Hiroaki Akamatsu, Dan Ye, Dhivya R. Sudhan, Lisa Eli, Katherine Marcelain, Benjamin P. Brown, Jens Meiler, Carlos L. Arteaga, Ariella B. Hanker

Cancer Res (2023) 83 (18): 3145–3158.

https://doi.org/10.1158/0008-5472.CAN-22-3617

Published: 15 September 2023

View articletitled, Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer

Includes: Supplementary data

Journal Articles

Abstract 3445: Immune cells infiltration and activation are higher in breast cancers resistant to antiestrogen therapy

Fabiana Napolitano, Dhivya R. Sudhan, Yunguan Wang, Paula I. González-Ericsson, Luigi Formisano, Kyung-Min Lee, Chang-Ching Lin, María Rosario Chica-Parrado, Hongli Ma, Nathaniel Evans, Alberto Servetto, Saurabh Mendiratta, Spencer Barnes, Yisheng V. Fang, Justin M. Balko, Gordon B. Mills, Marilyne Labrie, Ariella B. Hanker, Carlos L. Arteaga

Cancer Res (2023) 83 (7_Supplement): 3445.

https://doi.org/10.1158/1538-7445.AM2023-3445

Published: 04 April 2023

View articletitled, Abstract 3445: Immune cells infiltration and activation are higher in breast cancers resistant to antiestrogen therapy

Journal Articles

Abstract 3934: PRMT5 is an actionable target in CDK4/6 inhibitor-resistant ER+/Rb-deficient breast cancer

Cancer Res (2023) 83 (7_Supplement): 3934.

https://doi.org/10.1158/1538-7445.AM2023-3934

Published: 04 April 2023

View articletitled, Abstract 3934: PRMT5 is an actionable target in CDK4/6 inhibitor-resistant ER+/Rb-deficient breast cancer

Journal Articles

Abstract PD2-01: A platform of CDK4/6 inhibitor-resistant patient-derived breast cancer organoids illuminates mechanisms of resistance and therapeutic vulnerabilities

Cancer Res (2022) 82 (4_Supplement): PD2-01.

https://doi.org/10.1158/1538-7445.SABCS21-PD2-01

Published: 15 February 2022

View articletitled, Abstract PD2-01: A platform of CDK4/6 inhibitor-resistant patient-derived breast cancer organoids illuminates mechanisms of resistance and therapeutic vulnerabilities

Journal Articles

Abstract P4-01-02: A spectrum of secondary mutations in HER2 augment breast cancer cell growth and reduce neratinib sensitivity in HER2-mutant breast cancer

Arnaldo Andres Marin, Abdullah Al Mamun, Hiroaki Akamatsu, Dan Ye, Dhivya Sudhan, Benjamin Brown, Monica Red Brewer, Lisa Eli, Jens Meiler, Carlos L Arteaga, Ariella B Hanker

Cancer Res (2022) 82 (4_Supplement): P4-01-02.

https://doi.org/10.1158/1538-7445.SABCS21-P4-01-02

Published: 15 February 2022

View articletitled, Abstract P4-01-02: A spectrum of secondary mutations in HER2 augment breast cancer cell growth and reduce neratinib sensitivity in HER2-mutant breast cancer

Journal Articles

Abstract P5-17-09: A genome-wide CRISPR screen identifies PRMT5 as a novel therapeutic target in ER+/RB1-deficient breast cancer

Chang-Ching Lin, Tsung-Cheng Chang, Alberto Servetto, Kyung-min Lee, He Zhang, Yunguan Wang, Dan Ye, Sumanta Chatterjee, Dhivya R Sudhan, Hiroaki Akamatsu, Yang Xie, Joshua T Mendell, Ariella B Hanker, Carlos L Arteaga

Cancer Res (2022) 82 (4_Supplement): P5-17-09.

https://doi.org/10.1158/1538-7445.SABCS21-P5-17-09

Published: 15 February 2022

View articletitled, Abstract P5-17-09: A genome-wide CRISPR screen identifies PRMT5 as a novel therapeutic target in ER+/RB1-deficient breast cancer

Journal Articles

Abstract GS3-09: Loss of ASXL1 tumor suppressor promotes resistance to CDK4/6 inhibitors in ER+ breast cancer

Dhivya R. Sudhan, Sumanta Chatterjee, Jiwoong Kim, Yunguan Wang, Vishal Kandagatla, Dan Ye, Chang-Ching Lin, Jorge Gomez Tejeda Zanudo, Esha Jain, Arnaldo Marin, Alberto Servetto, Kyung-min Lee, Juan Manuel Povedano, David McFadden, Alex Barrett, Nikhil Wagle, Ariella B. Hanker, Carlos L. Arteaga

Cancer Res (2022) 82 (4_Supplement): GS3-09.

https://doi.org/10.1158/1538-7445.SABCS21-GS3-09

Published: 15 February 2022

View articletitled, Abstract GS3-09: Loss of ASXL1 tumor suppressor promotes resistance to CDK4/6 inhibitors in ER+ breast cancer

Journal Articles

Abstract GS1-06: FGFR1 associates with gene promoters and regulates gene transcription: Implications for endocrine resistance in ER+/FGFR1-amplified breast cancer

Alberto Servetto, Rahul Kollipara, Luigi Formisano, Chang-Ching Lin, Kyung-min Lee, Dhivya R Sudhan, Ariella B Hanker, Sumanta Chatterjee, Angel Guerrero-Zotano, Paula Gonzalez-Ericsson, Saurabh Mendiratta, Hiroaki Akamatsu, Nicholas James, Ralf Kittler, Carlos L Arteaga

Cancer Res (2021) 81 (4_Supplement): GS1-06.

https://doi.org/10.1158/1538-7445.SABCS20-GS1-06

Published: 15 February 2021

View articletitled, Abstract GS1-06: FGFR1 associates with gene promoters and regulates gene transcription: Implications for endocrine resistance in ER+/FGFR1-amplified breast cancer

Journal Articles

Abstract 3675: HER2 missense mutations in breast cancer cells do not alter HER2 internalization or sensitivity to T-DM1

Hiroaki Akamatsu, Rosa Mino, Marcel Mettlen, Dan Ye, Dhivya R. Sudhan, Albert Lin, Arnaldo Marin, Alberto Servetto, Kyung-min Lee, Sumanta Chatterjee, Sandra L. Schmid, Carlos L. Arteaga, Ariella B. Hanker

Cancer Res (2020) 80 (16_Supplement): 3675.

https://doi.org/10.1158/1538-7445.AM2020-3675

Published: 15 August 2020

View articletitled, Abstract 3675: HER2 missense mutations in breast cancer cells do not alter HER2 internalization or sensitivity to T-DM1

Journal Articles

Abstract 1304: FGFR1 associates with gene promoters and regulates transcription in ER+/FGFR1-amplified breast cancer: Implications for endocrine resistance

Alberto Servetto, Rahul Kollipara, Luigi Formisano, Kyung-min Lee, Albert Lin, Dhivya R. Sudhan, Ariella B. Hanker, Sumanta Chatterjee, Hiroaki Akamatsu, Arnaldo Marin, Saurabh Mendiratta, Ralf Kittler, Carlos L. Arteaga

Cancer Res (2020) 80 (16_Supplement): 1304.

https://doi.org/10.1158/1538-7445.AM2020-1304

Published: 15 August 2020

View articletitled, Abstract 1304: FGFR1 associates with gene promoters and regulates transcription in ER+/FGFR1-amplified breast cancer: Implications for endocrine resistance

Journal Articles

Abstract GS6-04: Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, breast cancer progression, and HER2 inhibitor sensitivity

Ariella B. Hanker, Harikrishna Sekar Jayanthan, Dan Ye, Chang-Ching Lin, Hiroaki Akamatsu, Jonathan H. Sheehan, James P. Koch, Dhivya R. Sudhan, Monica Red Brewer, Alberto Servetto, Jie He, Vincent A. Miller, Alshad S. Lalani, Jens Meiler, Carlos L. Arteaga

Cancer Res (2020) 80 (4_Supplement): GS6-04.

https://doi.org/10.1158/1538-7445.SABCS19-GS6-04

Published: 15 February 2020

View articletitled, Abstract GS6-04: Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, breast cancer progression, and HER2 inhibitor sensitivity

Journal Articles

Abstract PD7-04: Fibroblast growth factor receptor 1 associates with promoters genome-wide and regulates gene transcription in ER+/FGFR1-amplified breast cancer: Implications for endocrine resistance

Alberto Servetto, Rahul Kollipara, Luigi Formisano, Kyung-min Lee, Dhivya R Sudhan, Ariella B Hanker, Sumanta Chatterjee, Albert Lin, Saurabh Mendiratta, Nicholas James, Ralf Kittler, Carlos L Arteaga

Cancer Res (2020) 80 (4_Supplement): PD7-04.

https://doi.org/10.1158/1538-7445.SABCS19-PD7-04

Published: 15 February 2020

View articletitled, Abstract PD7-04: Fibroblast growth factor receptor 1 associates with promoters genome-wide and regulates gene transcription in ER+/FGFR1-amplified breast cancer: Implications for endocrine resistance

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 6297: Mapping cellular interactions from spatially resolved transcriptomics data

Abstract 5339: Single cell analysis enables tracking the evolution of resistance to CDK4/6 inhibitors in ER+ breast cancer

Abstract 3003: Targeting mechanisms of adaptive resistance to the PI3Kαmutant selective inhibitor RLY-2608 in HR+/PIK3CA mutant breast cancer

Abstract 5332: Targeting CDK2 in estrogen receptor-positive/RB-deficient breast cancer

Abstract CT271: Neoadjuvant targeted therapy in stage I-III HER2-mutant lobular breast cancer

Abstract 3308: A selective FGFR1/2 degrader overcomes endocrine resistance in ER+/FGFR1-amplified andFGFR1/2-mutant breast cancer

Abstract 7592: Combined inhibition of CDK4/6 and AKT is highly active against the luminal androgen receptor (LAR) subtype of triple negative breast cancer (TNBC)

AXL/WRNIP1 Mediates Replication Stress Response and Promotes Therapy Resistance and Metachronous Metastasis in HER2⁺ Breast Cancer

Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer

Abstract 3445: Immune cells infiltration and activation are higher in breast cancers resistant to antiestrogen therapy

Abstract 3934: PRMT5 is an actionable target in CDK4/6 inhibitor-resistant ER+/Rb-deficient breast cancer

Abstract PD2-01: A platform of CDK4/6 inhibitor-resistant patient-derived breast cancer organoids illuminates mechanisms of resistance and therapeutic vulnerabilities

Abstract P4-01-02: A spectrum of secondary mutations in HER2 augment breast cancer cell growth and reduce neratinib sensitivity in HER2-mutant breast cancer

Abstract P5-17-09: A genome-wide CRISPR screen identifies PRMT5 as a novel therapeutic target in ER+/RB1-deficient breast cancer

Abstract GS3-09: Loss of ASXL1 tumor suppressor promotes resistance to CDK4/6 inhibitors in ER+ breast cancer

Abstract GS1-06: FGFR1 associates with gene promoters and regulates gene transcription: Implications for endocrine resistance in ER+/FGFR1-amplified breast cancer

Abstract 3675: HER2 missense mutations in breast cancer cells do not alter HER2 internalization or sensitivity to T-DM1

Abstract 1304: FGFR1 associates with gene promoters and regulates transcription in ER+/FGFR1-amplified breast cancer: Implications for endocrine resistance

Abstract GS6-04: Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, breast cancer progression, and HER2 inhibitor sensitivity

Abstract PD7-04: Fibroblast growth factor receptor 1 associates with promoters genome-wide and regulates gene transcription in ER+/FGFR1-amplified breast cancer: Implications for endocrine resistance

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only